Neogenix Oncology Inactive 10-Q2011 Q2 Quarterly report

Filed: 15 Aug 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accelerate, accelerated, Albine, America, analytical, appointment, approach, banker, bear, bearing, bifurcated, Black, Bond, borrowed, borrowing, CAO, case, commensurate, companion, concept, consideration, consumer, corroborated, counsel, criteria, customary, departure, depository, discount, dividend, domestic, domestically, dosing, Dr, earliest, entirety, establish, established, expertise, explore, footnote, forfeited, globally, group, hiring, iii, individual, JHU, journal, law, Martin, matter, multinational, mutual, NEO, nonsubstantive, partnership, past, peer, promise, proof, proportionately, range, realigned, realignment, regular, reliance, residual, resignation, return, returned, salary, sector, serve, simplified, standalone, stated, straight, substantive, supplied, team, tumor, vendor

Removed: abroad, activity, adjusted, Administration, allocate, anticipated, arising, ASC, attributed, base, cell, cervical, CFO, charge, circumvented, Codification, collaboration, collected, collusion, comparability, conducted, dated, diligence, directly, discretion, disposition, earlier, enacted, ending, equivalent, escrow, examination, exit, facility, fact, failed, firm, Food, fully, gain, granting, guarantee, implemented, improper, increased, incurring, indirectly, input, intrinsic, involving, joint, largest, likelihood, lowest, lung, making, measure, measurement, Memorandum, minimal, month, nominal, noted, obtained, orderly, override, PPM, presently, prostate, receivable, reengineering, reflect, reflected, Reform, removed, requirement, resource, retired, revised, schedule, separately, September, settled, show, significantly, standard, sustained, therapy, tracking, transaction, transfer, type, ultimate, Unadjusted, unanticipated, undelivered, underpayment, unintentional, variety, vary, varying, venture, warranted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Neogenix Oncology similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Neogenix Oncology, Inc. on Form 10-Q for the quarter ended June 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the undersigned's best knowledge and belief:

(a)	the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(b)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Neogenix Oncology, Inc.

Date: August 15, 2011

	/s/ Philip M. Arlen, MD
	Philip M. Arlen, MD
	Chief Executive Officer
	(Principal Executive Officer)

	/s/ Dr. Albine Martin
	Dr. Albine Martin
	Chief Operating Officer and acting Chief Accounting Officer

A signed original of this written statement required by Section 906 has been provided to Neogenix and will be retained by us and furnished to the Securities and Exchange Commission or its staff upon request.